PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Antwerp University Hospital, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, UCLouvain, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Roswell Park Comprehensive Cancer Center, Aurora Health Care, Mayo Clinic, Emory University, Winship Cancer Institute, Oregon Health & Science University, University of Kansas Medical Center, Duke University, Duke Medical Center, Mayo Clinic Hospital, Seagen (United States), Universitair Ziekenhuis Leuven, KU Leuven
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3180174849